IQVIA Holdings Inc. $IQV Shares Acquired by Cerity Partners LLC

Cerity Partners LLC increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 12.5% in the fourth quarter, Holdings Channel reports. The firm owned 179,675 shares of the medical research company’s stock after buying an additional 19,958 shares during the quarter. Cerity Partners LLC’s holdings in IQVIA were worth $40,530,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Ameliora Wealth Management Ltd. acquired a new stake in IQVIA during the 4th quarter worth $25,000. International Assets Investment Management LLC acquired a new stake in IQVIA during the 4th quarter worth $27,000. Measured Wealth Private Client Group LLC acquired a new stake in IQVIA during the 3rd quarter worth $30,000. Activest Wealth Management boosted its stake in IQVIA by 590.0% during the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after purchasing an additional 118 shares during the period. Finally, Hilton Head Capital Partners LLC acquired a new stake in IQVIA during the 4th quarter worth $35,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Down 2.1%

Shares of IQVIA stock opened at $182.28 on Thursday. The company has a market cap of $30.42 billion, a P/E ratio of 22.59, a PEG ratio of 1.60 and a beta of 1.21. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA Holdings Inc. has a one year low of $153.01 and a one year high of $247.04. The firm has a fifty day moving average of $173.18 and a two-hundred day moving average of $194.08.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The company had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. IQVIA’s quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, analysts forecast that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA declared that its Board of Directors has initiated a share buyback plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

Wall Street Analyst Weigh In

IQV has been the subject of a number of recent research reports. Royal Bank Of Canada initiated coverage on shares of IQVIA in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target for the company. Barclays upgraded shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target for the company in a research note on Friday, March 6th. Evercore reiterated an “outperform” rating and set a $185.00 price target on shares of IQVIA in a research note on Wednesday, April 8th. HSBC set a $210.00 price objective on shares of IQVIA in a research report on Wednesday, June 3rd. Finally, Truist Financial cut their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research report on Thursday, February 19th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Buy” and an average target price of $224.13.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.